Abstract Background Glucantime is the first line agent for treatment of cutaneous leishmaniasis (CL). It has adverse effects on blood elements. This research has been done to evaluate the blood complications of this medicine in patients with cutaneous leishmaniasis. Methods This clinical trial was done at Nikpour clinic, Yazd, Iran. Blood samples were collected from patients diagnosed with ...

Background and aim: Cutaneous leishmaniasis is an endemic disease in Iran. Although there are many different treatments for this disease, there is not any effective treatment yet. Since there has been a number of different reports on the effectiveness of Cassia fistula plant in the treatment of leishmaniasis, the efficacy of concentrated boiled extract and hydro alcoholic extract of Cassi...

pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (cl). like other treatments, they can cause adverse reactions including musculoskeletal pain , gastrointestinal disturbances, and mild to moderate headaches. in this paper, we report the first case of an infant who developed acute urticaria after her mother’s parenteral use of meglumine antim...

Various chemical drugs have been used for leishmaniasis treatment, but their side effects and drug resistance have led to look for new effective compounds. Crataegus microphylla the traditional and medicinal herb is a valuable source of new Pharmaceutical agents. The extract were prepared The extract obtained by maceration method, and diluted with 5% DMSO. Leishmania major promastigotes were cu...

Cutaneous leishmaniasis (CL) can be seen in 2 forms, zoonotic and anthroponotic, in Iran. In this study, epidemiological aspects of CL were studied during an 8-year period (2009-2016) in city of Kashan, central Iran. The demographic and epidemiological data, including age, sex, occupation, number and site of the lesions, treatment regimen, past history of CL, and season of all patients were gat...

background: pentavalent antimonials are still the first choice treatment for leishmaniasis, but with low efficacy and resistance is emerging. in the present study, the effect of meglumine antimoniate (ma, glucantime) combined with paromomy-cin, miltefosine or allopurinol on in vitro susceptibility of leishmania tropica resistant isolate was evaluated. method : the drugs were obtained from comme...

The need for drug combinations to treat visceral leishmaniasis (VL) arose because of resistance to antimonials, the toxicity of current treatments and the length of the course of therapy. Calcium channel blockers (CCBs) have shown anti-leishmanial activity; therefore their use in combination with standard drugs could provide new alternatives for the treatment of VL. In this work, in vitro isobo...

BACKGROUND Successful therapy of leishmaniasis depends on effective cellular immune response. We evaluated the effectiveness of sodium selenite and zinc sulphate as known immunomodulator materials, in combination with Glucantime® in treatment of cutaneous leishmaniasis lesions resulting from Leishmania major in susceptible animal model. METHODS Thirty three female mice weighing 18-20 g at the...